East Rutherford-based Cambrex, a leading global contract development and manufacturing organization providing drug substance, drug product and analytical services across the entire drug lifecycle, announced Monday that it has entered into a definitive agreement to acquire Snapdragon Chemistry, a leading U.S.-based provider of chemical process development services.
Snapdragon specializes in active pharmaceutical ingredient batch and continuous flow process development, utilizing state-of-the-art automation technology and proprietary equipment to solve complex process and analytical development challenges.
The transaction is expected to close following the completion of customary regulatory approvals. This will be Cambrex’s second acquisition within a year, along with Q1 Scientific, consistent with its strategy to expand its portfolio of specialized solutions for pharmaceutical development and manufacturing.
With research & development and manufacturing headquartered in Waltham, Massachusetts, Snapdragon’s 74 employees come with strong ties to the local scientific community.
The team of scientists and engineers apply deep process understanding afforded by data-rich experimentation to design and rapidly execute efficient good manufacturing practice and non-GMP manufacturing processes.
Cambrex CEO Tom Loewald said the acquisition of Snapdragon will accelerate the company’s growth in the area of continuous flow process development and manufacturing. He said it would complement the company’s recent organic investments in its High Point, North Carolina, facility.
“With R&D and manufacturing capabilities in the heart of Boston’s biopharma hub, Snapdragon will continue to focus on solving their customers’ most difficult process development challenges,” he said.
